28/06/2007 13:00:00

Quantum Genomics Corp Partners with Inserm and CNRS in Hypertension Drug Development

Quantum Genomics Corp. (QGC), a global biotech company developing

new drugs for metabolic and cardiovascular diseases, announced

partnership agreements with Inserm, the French national institute for

health and medical research and the CNRS, France´s national center for

scientific research, and University Paris Descartes. The agreement

brings together some of the best scientific skills in the field of

cardiovascular diseases from two leading life science research

organizations and a premier university along with biotechnology

business experience from QGC, to successfully co-develop innovative


The agreement covers a lead molecule derived from discoveries by

teams led respectively by Dr Catherine Llorens-Cortes, director of

Inserm Unit 691, based in the College de France and by Prof. Bernard

P. Roques at Inserm Unit 640, itself based in the University of Paris


The purpose of the agreement is to co-develop innovative drugs for

hypertension and related cardiovascular diseases. Under the terms of

the contract, QGC acquires rights to exploit three patents and

associated know-how. Inserm and CNRS will work on the physiopathology,

chemistry and the understanding of the compound´s mechanism of action

whereas QGC will handle preclinical and clinical development and

regulatory aspects.

The first lead molecule to be developed will be QGC001, a new

chemical entity. This compound acts according to a new biological

mechanism with a huge potential to facilitate control of blood

pressure in patients who are resistant to currently available

anti-hypertension drugs. QGC expects to start the first clinical trial

in humans in 2008.

"We are delighted to be partnering with Inserm and CNRS, two of

the world´s leading healthcare research organizations," said Lionel

Segard, Chairman and CEO of QGC. "This project lets QGC demonstrate

its ability to develop new drugs in compliance with international

regulatory guidelines. It also significantly reinforces QGC´s

potential in R&D in the field of cardiovascular diseases."

"This partnership with QGC gives us an excellent opportunity to

accelerate the pre-clinical and clinical development of a project

based on work carried out in our labs in close cooperation with

Bernard Roques´ team," said Catherine Llorens Cortes, director of

Inserm Unit 691.

Cardiovascular diseases are one of the main causes of death in

humans. Hypertension in particular is one of the major determining

factors in premature death. The risk of myocardial infarction, stroke,

kidney failure, heart failure or other complications doubles with

every 20/10mmHg rise in blood pressure. At least 30% of people have

hypertension. Hundreds of millions of people worldwide suffer from

hypertension complications despite medical advice on food and health

habits and the existence of several treatments. The market for

hypertensive drugs is expected to double between 2005 and 2010.

About Quantum Genomics Corp.

QGC is a biotechnology company seeking to develop new therapies in

areas where an unmet medical need exists. QGC focus is on

metabolism-related diseases and cardiovascular pathologies. It will

co-develop some products with academic teams and will set up strategic

alliances and commercial partnerships to cover all areas of research

in life sciences.

The company is headquartered in Jersey City, New Jersey, USA. It

has a European office in France under the leadership of Lionel Segard.

For more information go to www.Quantum-Genomics.com

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
23 Nov
Mindre fnidder, mere aktiesnak! Vi har alle et ansvar for at ignorere de mange trolls.    Angående F..
26 Nov
Janssen ligeledes meget begejstret for DuoBody, så i løbet af nogle år får vi forhåbentlig for alvor..
25 Nov
Nå, nu er der gået et år siden jeg skrev sidst. Jeg vil starte med at pointere, at jeg er inhabil i ..
23 Nov
Vi nærmer os langsomt den nye verdensorden, og det er så tæt på, det ikke engang er sjovt mere! Vi ..
Indtil videre er det eneste der er kommet ud af COP 1, 2, 3......osv kun et ufatteligt miljøsvineri ..
23 Nov
Dabegaptide er et aktivt lægemiddelstof som tilhøre en hel ny klasse af lægemidler som muligvis kan ..
21 Nov
Jan Monrad er død. Her på siden kender vi Jan Monrad som direktør Åge Brodtgårds, Brodtgårds Legetøj..
21 Nov
I denne uge købte amerikansek Eli Lilly det canadiske selskab Locemia Solutions’s nasal glucagon pro..
26 Nov
Genmab og Janssens samarbejde om kræftlægemidlet Darzalex har forståeligt nok trukket mange overskri..
25 Nov
Hvad skal jeg gøre med de 4.000 ekstra Novo jeg købte igår i 376, 374, og 371,8 ??   På baggrund af ..

Form 8.3 - Royal Dutch Shell Plc

26/11/2015 15:25:14

Alliance Trust PLC : Net Asset Value(s)

26/11/2015 13:53:37
ALLIANCE TRUST PLC At the close of business on Wednesday 25 November 2015, the unaudited net asset value per ordinary share of 2.5p, valued on a bid pr..

PayPoint plc : Dividend Declaration

26/11/2015 08:29:08
26 November 2015 PayPoint plc - Interim Dividend The board of directors of PayPoint plc (the "Company") have declared an interim dividend of 14.2 penc..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
[ Iliad Press Release ] Successful placement of €650 million worth of seven-year bonds
FAIVELEY TRANSPORT announces it 2015/16 half-year results
RomReal :Third Quarter (Q3) Financial Results and Investor Presentation
Cegereal, the French Core Office REIT: Appointment of Ledouble as independant expert
Clariant AG: Clariant closes strategic alliance with Beraca acquiring 30% of its shares in Health & Personal Care Division

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2015   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
27 November 2015 15:23:15
(UTC) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20151126.1 - EUROWEB7 - 2015-11-27 16:23:15 - 2015-11-27 15:23:15 - 1000 - Website: OKAY